New online tool aims to simplify kidney cancer treatment decisions
NCT ID NCT05387863
First seen Jan 05, 2026 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This study tests a web-based decision aid for people with small kidney tumors (up to 4 cm). The tool provides personalized information about treatment options and their risks and benefits. Researchers will enroll 40 patients to see if the tool improves knowledge, satisfaction, and shared decision-making compared to a standard pamphlet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decision Aid Web Tool
What this could lead to
If successful, this tool could help patients and doctors make better, more personalized decisions about treating small kidney tumors.
What could go wrong
This is a small, early-stage study (40 participants) that only measures decision-making, not health outcomes. The tool may not improve actual treatment results.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.